6. 8

PE 7035

RECEIVED

Sheet \_ 1\_ of \_2\_

**FORM PTO-1449** 

PATENT AND THE PATENT

ATINO O O SERIAL NO. 09/818,875

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT
Eric B. Kmiec et al.

FILING DATE GROUP March 27, 2001 1635

U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT NUMBER | DATE     | NAME     | CLASS | SUBCLASS | FILING DATE<br>IF<br>APPROPRIATE |
|---------------------|-----------------|----------|----------|-------|----------|----------------------------------|
| 758                 | 5,565,350       | 10/15/96 | Kmiec    | 435   | 172.3    |                                  |
| Des                 | 5,731,181       | 3/24/98  | Kmiec    | 435   | 172.3    |                                  |
| Sec                 | 5,912,340       | 6/15/99  | Kutyavin | 536   | 24.5     |                                  |
| Ser                 | 6,004,804       | 12/21/99 | Kumar    | 435   | 320.1    |                                  |
| 9                   | 6,271,360       | 8/7/01   | Metz     | 536   | 23.1     |                                  |

FOREIGN PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT NUMBER | DATE    | COUNTRY | CLASS | SUBCLASS | TRANSLATION |                                       |
|---------------------|-----------------|---------|---------|-------|----------|-------------|---------------------------------------|
|                     |                 |         |         |       |          | YES         | NO                                    |
| a/                  | WO 99/14226     | 3/25/99 | PCT     |       |          |             |                                       |
| 2                   | WO 00/56748     | 9/28/00 | PCT     |       |          |             |                                       |
| 9                   | WO 00/66604     | 11/9/00 | PCT     |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
| <u> </u>            |                 |         |         |       |          |             |                                       |
|                     | -               |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       | ļ        |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             | · · · · · · · · · · · · · · · · · · · |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |
|                     |                 |         |         |       |          |             |                                       |

**EXAMINER** 

DATE CONSIDERED 5-20-02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.





MAR 2 0 2002

Sheet 2 of 2

**FORM PTO-1449** 

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADELARK OFFICE

**APPLICANT** 

SERIAL NO. 09/818,875

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Eric B. Kmiec et al.

**FILING DATE** March 27, 2001 **GROUP** 1635

|                  | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  |  |  |  |  |  |
|------------------|---|--|--|--|--|--|
| EXAMINER INITIAL |   |  |  |  |  |  |
| 8                | Alexeev & Yoon, "Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide," Nature Biotech. 16:1343-1346 (1998)   |  |  |  |  |  |
| V                | Campbell et al., "Homologous recombination involving small single-stranded oligonucleotides in human cells," New Biologist 1:223-227 (1989)   |  |  |  |  |  |
| 8                | Chan & Glazer, "Triplex DNA: fundamentals, advances, and potential applications for gene therapy," <u>J. Mol. Med.</u> 75:267-282 (1997)  |  |  |  |  |  |
| $\mathcal{A}$    | Chan et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide," <u>J. Biol. Chem.</u> 274:11541-11548 (1999)   |  |  |  |  |  |
| 3                | Cole-Strauss et al., "Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide," Science 273:1386-1389 (1996)  |  |  |  |  |  |
| 9                | Culver et al., "Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides," Nat. Biotechnol., 17:989-993 (1999)   |  |  |  |  |  |
| Q                | Gamper et al., "The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts," Nucleic Acids Res. 28:4332-4339 (2000)   |  |  |  |  |  |
| 9                | Igoucheva et al., "Targeted gene correction by small single-stranded oligonucleotides in mammalian cells," Gene Therapy 8:391-399 (2001)  |  |  |  |  |  |
| 8                | Kren et al., "Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide," <a href="Proc. Natl. Acad. Sci. USA">Proc. Natl. Acad. Sci. USA</a> 96:10349-10354 (1999) |  |  |  |  |  |
| 6                | Kunzelmann et al., "Gene targeting of CFTR DNA in CF epithelial cells," Gene Ther. 3:859-867 (1996)   |  |  |  |  |  |
| 9                | Moerschell et al., "Transformation of yeast with synthetic oligonucleotides," Proc. Natl. Acad. Sci. USA 85:524-528 (1988)  |  |  |  |  |  |
| 8                | Rando et al., "Rescue of dystrophin expression in <i>mdx</i> mouse muscle by RNA/DNA oligonucleotides,"<br>Proc. Natl. Acad. Sci. USA 97:5363-5368 (2000)   |  |  |  |  |  |
| 0//              | Vasquez et al., "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," Nucl. Acids Res. 27:1176-1181 (1999)  |  |  |  |  |  |
| 06               | Vasquez et al., "Specific mutations induced by triplex-forming oligonucleotides in mice," <u>Science</u> 290:530-532 (2000)   |  |  |  |  |  |
| <b>Y</b> /       | Yamamoto et al., "Strand-specificity in the transformation of yeast with synthetic oligonucleotides," <u>Genetics</u> 131:811-819 (1992)  |  |  |  |  |  |
|                  | Yanez & Porter, "Therapeutic gene targeting," Gene Therapy 5:149-159 (1998)   |  |  |  |  |  |
| <i>y</i>         | Xu et al., "Activation of human $\gamma$ -globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the $\gamma$ -globin gene 5' flanking region," Gene 242:219-228 (2000)   |  |  |  |  |  |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.